Bio-Techne resumed with an Outperform at RBC Capital

RBC Capital resumed coverage of Bio-Techne (TECH) with an Outperform rating and $62 price target Bio-Techne is the most levered company to the improved biotech funding environment in the firm’s coverage, the analyst tells investors in a research note, also stating that the Buy rating reflects RBC’s confidence that sales growth will rebound and company’s planned acquisition of Wilson Wolf is underappreciated. While waiting for the market rebound, the company is not sitting still, but rather executing on multiple initiatives to improve its business mix and efficiency, the firm added.